ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

olatorepatide

Also written as “Olatorepatide”, “HS-20094” and “HS-20094 Injection”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Hidradenitis Suppurativa · Overweight, led by 2 companies.

Drug pageOlatorepatide: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 18, 202512 company-led studies, 7 open or runningLicense: Hansoh → Regeneron, Jun 2025Next primary completion: Mar 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Groupits history only83 open or runningphase 3since Feb 18, 2025Oct 29, 2021Mar 30, 2027phase 3 · NCT07156500
Regeneron Pharmaceuticals44 open or runningphase 3since Oct 19, 2026Feb 18, 2026Jan 21, 2028phase 2 · NCT07685808
  • Named in Hansoh Pharmaceutical Group’s own pipeline as Olatorepatide (HS-20094), phase 4, as of Aug 26, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Regeneron Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 29, 2024Named olatorepatideINNProposed as its International Nonproprietary Name in WHO's List 130 · before, HS-20094
  2. Jun 2, 2025Regeneron licensed it from HansohLicenseEverywhere outside mainland China, Hong Kong and Macau · announced · Regeneron
  3. Feb 18, 2026First study: phase 2 study in OverweightFirst studyNCT07431086 · 120 enrolled · United States
  4. Jun 29, 2026Phase 2 study in OverweightNCT07685808 · 360 planned · United States
  5. Sep 15, 2026Phase 2 study in Hidradenitis SuppurativaNCT07830329 · 300 planned · United States
  6. Oct 19, 2026Phase 3 study in OverweightPhase 3 reachedNCT07896265 · 3,000 planned

Ahead

  1. Nov 13, 2026Primary completion: phase 2 study in OverweightNCT07431086
  2. Jan 21, 2028Primary completion: phase 2 study in OverweightNCT07685808
  3. Nov 24, 2028Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07830329
  4. Dec 19, 2028Primary completion: phase 3 study in OverweightNCT07896265

TargetBeta

“A Phase 3, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living With Overweight or Obesity Without Diabetes (RISE-1)”study text, read by Claude · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
TirzepatideruleEli Lillyphase 472
retatrutideruleEli Lillyphase 333
brenipatideEli Lillyphase 319
UBT251The United Laboratories Internationalphase 312
enicepatideHoffmann-La Rochephase 310
VK2735ruleViking Therapeuticsphase 38
NNC0519-0130Novo Nordiskphase 211
BI 3034701Boehringer Ingelheimphase 26
HRS-4729Jiangsu HengRui Medicinephase 25
NA-931rulebiomed-industries-incphase 23

Studies

All 4 Regeneron Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07896265Overweight3Not yet recruitingDec 19, 20283,000
NCT07830329Hidradenitis Suppurativa · United States2RecruitingNov 24, 2028300
NCT07685808Overweight · United States2RecruitingJan 21, 2028360
NCT07431086Overweight · United States2Active, not recruitingNov 13, 2026120

How it is read

Names in the registry

  • “Olatorepatide”, 4 entries
  • “HS-20094”, 3 entries
  • “HS-20094 Injection”, 3 entries
  • “HS-20094 injection”, 1 entry
  • “HS-20094 5mg”, 1 entry

Codes read as this program: HS20094.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.